{"id":"gbp510-adjuvanted-with-as03","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GBP510 contains recombinant protein antigens that are presented to the immune system to generate both cellular and humoral immune responses. AS03 is an oil-in-water adjuvant that amplifies and accelerates the immune response to the vaccine antigen, improving efficacy and potentially broadening the immune response profile. This combination approach is typical for next-generation vaccine development to enhance protection against infectious diseases or cancer.","oneSentence":"GBP510 is a recombinant protein subunit vaccine designed to stimulate immune responses against a specific pathogen or disease target, formulated with AS03 adjuvant to enhance immunogenicity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:42.746Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Respiratory syncytial virus (RSV) infection in older adults (most likely indication based on SK Bioscience pipeline)"}]},"trialDetails":[{"nctId":"NCT05501522","phase":"PHASE3","title":"Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2022-12-09","conditions":"COVID-19","enrollment":840},{"nctId":"NCT05007951","phase":"PHASE3","title":"Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2021-08-30","conditions":"Covid19","enrollment":4036},{"nctId":"NCT05175950","phase":"PHASE2","title":"Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)","status":"UNKNOWN","sponsor":"Korea University Guro Hospital","startDate":"2022-01-24","conditions":"COVID-19 (Healthy Volunteers)","enrollment":770},{"nctId":"NCT04750343","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)","status":"UNKNOWN","sponsor":"SK Bioscience Co., Ltd.","startDate":"2021-02-03","conditions":"COVID-19 (Healthy Volunteers)","enrollment":328}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GBP510 adjuvanted with AS03","genericName":"GBP510 adjuvanted with AS03","companyName":"SK Bioscience Co., Ltd.","companyId":"sk-bioscience-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"GBP510 is a recombinant protein subunit vaccine designed to stimulate immune responses against a specific pathogen or disease target, formulated with AS03 adjuvant to enhance immunogenicity. Used for Respiratory syncytial virus (RSV) infection in older adults (most likely indication based on SK Bioscience pipeline).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}